NCT03205137View on ClinicalTrials.gov

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

June 1, 2022

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Hypertension
Interventions
DRUG

subjects treated with telmisartan/hydrochlorothiazide

subjects treated with telmisartan/hydrochlorothiazide

DRUG

Subjects treated with Telmisartan and amlodipine

Subjects treated with Telmisartan and amlodipine

DRUG

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group

DRUG

subjects treated with telmisartan+amlodipine double pill

subjects treated with telmisartan+amlodipine double pill

Trial Locations (1)

141-6017

Nippon Boehringer Ingelheim Co., Ltd., Tokyo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY